These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29926358)

  • 21. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis.
    Wade R; Sideris E; Paton F; Rice S; Palmer S; Fox D; Woolacott N; Spackman E
    Health Technol Assess; 2015 Nov; 19(98):1-220. PubMed ID: 26613365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin.
    Janzic A; Locatelli I; Kos M
    Am J Cardiovasc Drugs; 2017 Oct; 17(5):399-408. PubMed ID: 28528365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of decision analytic modeling in the health economic assessment of spinal intervention.
    Edwards NC; Skelly AC; Ziewacz JE; Cahill K; McGirt MJ
    Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S16-42. PubMed ID: 25299257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A rational framework for decision making by the National Institute For Clinical Excellence (NICE).
    Claxton K; Sculpher M; Drummond M
    Lancet; 2002 Aug; 360(9334):711-5. PubMed ID: 12241891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new approach for sample size calculation in cost-effectiveness studies based on value of information.
    Bader C; Cossin S; Maillard A; Bénard A
    BMC Med Res Methodol; 2018 Oct; 18(1):113. PubMed ID: 30348087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical decision making and the expected value of information.
    Willan AR
    Clin Trials; 2007; 4(3):279-85. PubMed ID: 17715257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods.
    Chen MH; Willan AR
    Clin Trials; 2013 Feb; 10(1):54-62. PubMed ID: 23263520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budget impact analysis.
    Leelahavarong P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Hodgson R; Walton M; Biswas M; Mebrahtu T; Woolacott N
    Pharmacoeconomics; 2018 Apr; 36(4):387-398. PubMed ID: 29192397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model.
    Tappenden P; Chilcott J; Brennan A; Squires H; Glynne-Jones R; Tappenden J
    Value Health; 2013 Jun; 16(4):542-53. PubMed ID: 23796288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
    Rogowski WH; Landauer M; John J
    Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model Structuring for Economic Evaluations of New Health Technologies.
    Haji Ali Afzali H; Bojke L; Karnon J
    Pharmacoeconomics; 2018 Nov; 36(11):1309-1319. PubMed ID: 30030816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved?
    Drummond M
    J Health Polit Policy Law; 2013 Dec; 38(6):1081-102. PubMed ID: 23974475
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.